IRCT20141025019669N21 IRCT 2022-01-23 Qazvin University of Medical Sciences Ellagic acid supplementation in patients with non-alcoholic fatty liver disease Assessment of the Ellagic acid supplementation effect on lipid profile, liver enzymes, oxidative stress status and inflammatory factors in patients with non-alcoholic fatty liver disease: double-blind randomized clinical trial 2022-01-21 anticipated 44 Complete https://irct.ir/trial/60959 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: It will be done randomly using the lottery method. Each patient will receive a number or code, and then we will write the numbers on pieces of paper. We will then place the pieces of paper in a container and select the samples according to the sample size, Blinding description: Supplements and placebo will be placed in similar containers and encoded by someone except the investigator, so patients and the investigator will be blinded to medicine and placebo groups. 3 Non alcoholic fatty liver disease. Intervention 1: Intervention group: Ellagic acid, a capsule 180 mg per daily for two months, Manufacturer: Supplement Spot. Intervention 2: Control group: A daily placebo capsule containing wheat flour for two months. Yes - There is a plan to make this available What will be shared: All data after people are unrecognizable When: After completing the study and publishing the article To whom: All researchers Conditions: There is nothing wrong with using the data as long as the source of the data is mentioned. Where to obtain: By contacting the email address of a person responsible for general inquiries khademnut@yahoo.com How to obtain: After consulting with the research team, the data will be provided to the applicant, which will probably be a one-month process. Comments: